Sarcoma Foundation of America Announces 2020 Research Grant Awards
May 28, 2020 11:57 ET
|
Sarcoma Foundation of America
Damascus, MD, May 28, 2020 (GLOBE NEWSWIRE) -- The Sarcoma Foundation of America (SFA), an organization dedicated to increasing research and awareness for sarcoma, today announced that it has...
Sarcoma Foundation of America Announces Brandi Felser as Executive Director
February 03, 2020 08:53 ET
|
Sarcoma Foundation of America
Damascus, MD, Feb. 03, 2020 (GLOBE NEWSWIRE) -- The Sarcoma Foundation of America (SFA), an organization dedicated to increased research, awareness and advocacy for sarcoma, announces Brandi Felser...
Clear Benefit for Patients with Synovial Sarcoma Demonstrated in Updated Data from Ongoing Phase 1 Trial with ADP-A2M4 Presented at ESMO
September 30, 2019 08:45 ET
|
Adaptimmune Therapeutics plc
PHILADELPHIA and OXFORDSHIRE, United Kingdom, Sept. 30, 2019 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, presented updated...
TLC to Present Preclinical Data on TLC178 at ESMO 2019
September 23, 2019 05:00 ET
|
TLC
SOUTH SAN FRANCISCO, Calif. and TAIPEI, Taiwan, Sept. 23, 2019 (GLOBE NEWSWIRE) -- TLC (Nasdaq: TLC, TWO: 4152), a clinical-stage specialty pharmaceutical company dedicated to the development and...
Adaptimmune Starts SPEARHEAD-1 Trial with ADP-A2M4 SPEAR T-cells for patients with Synovial Sarcoma or MRCLS
July 25, 2019 08:00 ET
|
Adaptimmune Therapeutics plc
- Compelling data reported with ADP-A2M4 SPEAR T-cells in synovial sarcoma - - Adaptimmune plans to launch a TCR T-cell therapy in 2022 - PHILADELPHIA and OXFORDSHIRE, United Kingdom, July 25, 2019...
NANOBIOTIX: Positive phase II/III results for NBTXR3 in Soft Tissue Sarcoma presented at ESMO
October 19, 2018 12:05 ET
|
NANOBIOTIX
NANOBIOTIX: POSITIVE PHASE II/III RESULTS FOR NBTXR3 IN SOFT TISSUE SARCOMA PRESENTED AT ESMO Dr. Sylvie Bonvalot, Head of Sarcoma and Complex Tumor Surgery Unit at Institut Curie - Paris,...
NANOBIOTIX : Résultats positifs de la Phase II/III dans les Sarcomes des Tissus Mous avec NBTXR3 présentés à l’ESMO
October 19, 2018 12:05 ET
|
NANOBIOTIX
NANOBIOTIX : RESULTATS POSITIFS DE LA PHASE II/III DANS LES SARCOMES DES TISSUS MOUS AVEC NBTXR3 PRESENTES A L’ESMO Dr. Sylvie Bonvalot, Chef du Service Sarcomes et Tumeurs Complexes de...
Study published in Cancer Discovery Indicates that NY-ESO SPEAR T-cells are Long-lived, Self‑renewing, and Capable of Persistent Anti-Tumor Effects
June 11, 2018 07:30 ET
|
Adaptimmune Therapeutics plc
PHILADELPHIA and OXFORD, United Kingdom, June 11, 2018 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced that data from the...
Updated Myxoid/Round Cell Liposarcoma Data with NY-ESO, Presented at ASCO Annual Meeting, Further Supports Promising Benefit: Risk Profile
June 02, 2018 08:00 ET
|
Adaptimmune Therapeutics plc
PHILADELPHIA and OXFORD, United Kingdom, June 02, 2018 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, presented initial data from the...
Immune Design Announces Launch of Web Portal for SYNOVATE Phase 3 Study of CMB305 Immunotherapy in Synovial Sarcoma
May 24, 2018 08:00 ET
|
Immune Design Corp.
-- 1st global Phase 3 trial focused on synovial sarcoma patients -- www.synovatestudy.com SEATTLE and SOUTH SAN FRANCISCO, Calif., May 24, 2018 (GLOBE NEWSWIRE) -- Immune...